Christopher V Almario, DDW 2022: An Interactive Decision Making Tool for Inflammatory Bowel Disease
There are many challenges in selecting biologic therapies for patients with inflammatory bowel disease. touchIMMUNOLOGY were delighted to speak with Dr. Christopher V. Almario (Cedars Sinai Medical Center, Los Angeles, CA, USA) around his presentation discussing the clinical trial assessing the IBD&Me decision making tool.
The abstract ‘IMPACT OF AN INTERACTIVE IBD BIOLOGICS DECISION AID ON PATIENT OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL.’ (Abstract number: 982) was presented at Digestive Disease Week 2022, May 21-24, 2022.
- What are the challenges in selecting biologic therapies for patients with inflammatory bowel disease? (0:12)
- Could you give us a brief overview of the IBD&Me decision making tool? (0:54)
- Could you tell us a little about the clinical trial assessing this tool, and its findings? (2:31)
- What do you think were the reasons for the lack of difference between the study arms? (5:15)
- What should be the focus of future studies? (6:54)
Disclosures: Christopher Almario discloses consulting for Arena Pharmaceuticals and receiving grant/ research support from the Crohn’s & Colitis Foundation.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of DDW 2022.
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!